Dear Investors,
Frenelle Pharma is developing next-generation long-acting injectable therapeutics using its proprietary Faros™ drug-delivery platform. Its lead program, FRN01, is a 30-day subcutaneous buprenorphine injection being developed for Opioid Use Disorder (OUD).
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing to learn more about Frenelle’s differentiated approach, development progress, and investment opportunity.
Why Investors Are Taking Notice
Large, Underpenetrated Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, yet reaches less than 10% of patients treated for OUD.
Differentiated Product — FRN01 is designed to provide monthly treatment while addressing key patient and access barriers.
Validated Technology — Frenelle’s Faros™ platform has been clinically validated, with FRN01 demonstrating formulation proof of concept.
Near-Term Milestones — Frenelle is advancing formulation optimization, IND-enabling studies, and an FDA pre-IND meeting.
